Bpc-157

• Jul 3, 2026 BPC-157 and the Research-Peptide Gray Market

  BPC-157 has a real, unusually stable structure and a genuinely striking animal-trial record — and almost no controlled human data, an FDA compounding ban, and a supply chain that self-injects with no regulatory floor under it. Here's what the evidence actually supports.

• Jul 2, 2026 The Huberman Lab Peptides Episode, Reviewed: What Dr. Bakri Said and What Survives Scrutiny

  In June 2026, Andrew Huberman spent nearly three hours with physician Abud Bakri walking through BPC-157, GHK-Cu, epithalon, pinealon, thymosin alpha-1, GLP-1s, and retatrutide. The episode is a genuinely useful map of what people are injecting and why. It is also a case study in how conversational time can flatten a very steep evidence gradient. A peptide-by-peptide fact-check of the claims, the mechanisms, and the regulatory maze in between.